Curing HA® is a solid cross-linked hyaluronic acid medical biopolymer exclusively developed by USCarePharm. It is an upgraded version that improves upon the physical, chemical, and functional limitations of traditional hyaluronic acid.

Conventional cross-linked hyaluronic acid production processes require a minimum of 150 hours and up to 400 hours, involving complex and demanding steps that make large-scale production challenging and limit the ability to produce high-purity, high-performance raw materials.

USCarePharm’s CUHA Tech™ technology overcomes these barriers, enabling the stable, large-scale production of high-purity, high-performance solid cross-linked hyaluronic acid, Curing HA®.

Based on this technology, the Curing HA® Series is widely used in various medical and biomedical fields, including dermal fillers, joint injections, pharmaceutical drug delivery systems (DDS), and dental materials.